Phase II Prospective Multicenter Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma.

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518912-37-01

Acronym

INES

Enrollment

Registered

2024-12-09

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ewing Sarcoma

Brief summary

• Frequency, duration, and severity of Adverse Effects (AEs) and Serious Adverse Effects (SAEs) according to CTCAE v. 5.0 • Event-Free Survival at 36 months defined as the time from the start of chemotherapy to disease progression, relapse, second malignancies, death from treatment-related complications, or the last follow-up

Detailed description

Overall Survival at 36 months defined as the time from the start of chemotherapy to death or the last follow-up

Interventions

DRUGIFOSFAMIDE

DRUGDOXORUBICIN

DRUGMELPHALAN

DRUGVINCRISTINE

DRUGCYCLOPHOSPHAMIDE

DRUGTrecondi 1 g powder for solution for infusion

DRUGETOPOSIDE

DRUGTrecondi 5 g powder for solution for infusion

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
• Frequency, duration, and severity of Adverse Effects (AEs) and Serious Adverse Effects (SAEs) according to CTCAE v. 5.0 • Event-Free Survival at 36 months defined as the time from the start of chemotherapy to disease progression, relapse, second malignancies, death from treatment-related complications, or the last follow-up	—

Secondary

Measure	Time frame
Overall Survival at 36 months defined as the time from the start of chemotherapy to death or the last follow-up	—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026